Parkinsons Market Analysis and Reports | USA Conference Series

Market Analysis - Parkinsons 2017

Theme: Research Strategies, propelled advancements and developments in Parkinson’s disease.

On behalf of the Conference Organizing Committee, It is our heartiest welcome you to the “3rd International conference on Parkinson's Disease and Movement Disorders” during September 25-26, 2017 in Chicago, USA.

 

Importance and Scope:

Parkinson’s disease is a progressive disease of the nervous system set apart by tremor, muscle rigidity, and moderate, imprecise movement, chiefly affecting aged and elderly individuals. It is connected with degeneration of the basal ganglia of the brain and deficiency of the neurotransmitter dopamine.

Parkinson’s disease is a progressive neurological disorder which is caused due to neurodegeneration.About 10 million of people are suffering from Parkinson’s disease globally. The global prevalence in 2012 was approximately 2.18 million cases in worldwide where $1.15 billion in US market. The Parkinson’s disease market in US is expected to grow at a rate of 7.3% from sales of of $1.1 billion in 2012 to $2.3 billion in 2022.Treatment market value is being expected to increase from $3.6 billion in 2012 to $5.3 billion in 2022. US- has the largest Parkinson’s disease therapeutics market share of 44% by 2022 which is expanding from 32% in 2012 and this will be followed by Japan, Brazil and Germany with shares of 13%, 11% and 10%. Approximately 1 million adults in USA are suffering from Parkinson’s disease, from where 60,000 were diagnosed annually. In the United Kingdom approximately 127,000 people are suffering from PD. Male got 50% higher risk than females, however 4 to 5% of the cases the sufferer is younger than 40 years and it is known as Young-onset Parkinson’s disease.  NINDS funded about $90 million out of $135 million in NIH-supported PD research in USA. 

For more details, please visit: http://parkinsons.conferenceseries.com/

Why Chicago:

 Parkinson’s 2017 are the leading meeting dedicated to Neurologists and Neurosurgeons researchers with the theme “

Goal of Parkinson’s2017 is to deliver an outstanding program for exchange of ideas and authoritative views by leading scientists which covers the entire spectrum of research in Parkinson’s Disease and Movement Disorders and share the cross-cultural experiences of various treatment procedures.

We strive to make Parkinson’s 2017 a success, with your support and high quality talks from both Parkinson’s disease and Movement Disorders communities. During the conference, we assure you that you will experience world class facilities and hospitality at the conference.

Approximately 1 million adults in USA are suffering from Parkinson’s disease, from where 60,000 were diagnosed annually. An estimated of 40%-60% of PD patients mainly suffering from depression. United States is in the fourth position in considering the death of people due to Parkinson’s disease

Parkinson’s 2017 Organising Committee, invites all the participants from all over the world to attend the Parkinson’s 2017 conference entitled “3rd International conference on Parkinson's Disease and Movement Disorders” during September 25-26, 2017 at Chicago, USA. This gathering is predominantly will focus the most recent and energizing developments in each range of Parkinson’s research, and it will offer an exceptional opportunity for specialists from all over  the world to meet, network, and distinguish with different scientific interactions.

Parkinson’s disease is a dynamic neurological disorder that influences how the individual moves, including how they talk and compose. This disease is caused by low dopamine levels. Various useful treatments, utilizing therapies (physiotherapy), surgery and medications have recognized neurological disorders and changes in the patient group. People with Parkinson’s disease also experience stiffness and they find abnormality in carrying out the movements as rapidly as before- this is known as bradykinesia.

The Parkinson’s disease market in US is expected to grow at a rate of 7.3% from sales of of $1.1 billion in 2012 to $2.3 billion in 2022. Approximately 1 million adults in USA are suffering from Parkinson’s disease, from where 60,000 were diagnosed annually. An estimated of 40%-60% of PD patients mainly suffering from depression. United States is in the fourth position in considering the death of people due to Parkinson’s disease. African Americans have the highest death rate of 66.4% followed by whites of 64.6%, Hispanic with 55.4% and Asians with 50.8%. Parkinson’s disease strikes 50% more men than women. The economic burden of Parkinson’s disease on patients and their families in the U.S is about $14.4 billion.